Published in Blood Weekly, December 1st, 2005
Because of its convenience and ease of use, the SCDAA believes that the availability of Exjade will present a significant advancement in the treatment of chronic iron overload, and could help many patients who are unable to comply with infusion therapy, or who are not being treated for their iron overload.
This article was prepared by Blood Weekly editors from staff and other reports. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.